Skip to main content
UniHealth

Doctor search

Zoe Eloise Quandt

Endocrinology · San Francisco

NPI 1861735714

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
5

Offices

5 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Zoe Eloise Quandt’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A131799 · Current

Licensed to practise in California · since 2014 · expires 2028-01-31 · University of California San Francisco School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$19,528

Medicare paid this office $19,528 for 87 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)50$6,779$82
Long return visit (40+ min)23$4,325$120
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes17$1,961$115

Who their Medicare patients are

87 Original Medicare patients in 2024. Average age 70 · Women 39% · Also on Medicaid 26% · Health risk score 3.14. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.

Conditions among them: High blood pressure 71% · Diabetes 51% · Chronic kidney disease 41% · Coronary heart disease 40% · Cancer 36% · Heart failure 32% · Atrial fibrillation 31% · Depression 21% · COPD 18% · Stroke 13%.

The office billed $134,533, Medicare allowed $25,519 and paid $19,528; for 326 services of 19 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202487326703.14$134,533$19,528
202378311702.20$134,092$18,996
202265242692.21$127,069$20,998
202153103682.65$70,838$11,019
202054141671.92$86,354$11,355
20192757701.89$42,403$4,912
20182025681.03$21,385$2,758

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Return visit (30+ min)44$5,989$83
Long return visit (40+ min)35$5,708$114

2022: 2 services

Original Medicare services billed in 2022
Long return visit (40+ min)39$9,013$125
Return visit (30+ min)47$5,879$79

2021: 2 services

Original Medicare services billed in 2021
Long return visit (40+ min)35$6,942$122
Return visit (30+ min)15$1,349$79

2020: 2 services

Original Medicare services billed in 2020
Long return visit (40+ min)30$5,442$99
Return visit (30+ min)23$2,915$66

2019: 2 services

Original Medicare services billed in 2019
Return visit (30+ min)17$1,635$63
New patient visit (60+ min)12$1,427$119

2018: 1 service

Original Medicare services billed in 2018
New patient visit (60+ min)11$1,639$149

Medicaid work

$1,457 in 2023

Medicaid paid $1,457 for 13 billed services this clinician did in 2023, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES13$1,457
Medicaid work by year
202313113$1,457

Drugs they prescribed that Part D paid

$87,842

Pharmacies billed $87,842 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 367) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.

174 generic and 170 brand-name prescriptions · $87,842 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Testosterone31$6,266$202
Tradjenta12$6,174$515
Hydrocortisone55$3,590$65
Nano 2nd Gen Pen Needle15$1,216$81
Levothyroxine76$1,099$14
See all 7 drugs
Every Part D drug this clinician prescribed
Testosterone31$6,266$202
Tradjenta12$6,174$515
Hydrocortisone55$3,590$65
Nano 2nd Gen Pen Needle15$1,216$81
Levothyroxine76$1,099$14
Cabergoline12$756$63
Humalog11$739$67

Year by year

Part D prescribing by year
2024367550% (0)46%$87,842
2023260470% (0)41%$66,921
2022298500% (0)42%$60,082
2021253480% (0)None$71,302
2020136350% (0)54%$37,714
201983200% (0)72%$12,903
201875190% (0)None$5,206
201750150% (0)48%$6,383

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Testosterone19$7,213$380
Hydrocortisone67$4,622$69
Levothyroxine54$1,141$21
Metformin Hcl Er14$399$29

2022: 6 drugs

Part D drugs prescribed in 2022
Testosterone19$4,580$241
Hydrocortisone54$3,035$56
Levothyroxine83$1,494$18
Cabergoline13$794$61
Prednisone11$302$27
Metformin Hcl Er21$270$13

2021: 4 drugs

Part D drugs prescribed in 2021
Testosterone24$5,133$214
Hydrocortisone61$4,677$77
Levothyroxine52$1,280$25
Cabergoline20$1,156$58

2020: 2 drugs

Part D drugs prescribed in 2020
Hydrocortisone26$1,333$51
Levothyroxine31$896$29

2019: 2 drugs

Part D drugs prescribed in 2019
Hydrocortisone24$677$28
Levothyroxine28$492$18

2018: 1 drug

Part D drugs prescribed in 2018
Levothyroxine26$655$25

2017: 1 drug

Part D drugs prescribed in 2017
Levothyroxine18$432$24

Money from drug and device companies

$6,218 in 2025

Industry payments by year
202527$5,687$6,218
202415None$958
202314$6,088$6,319
202216$8,289$8,289
201911None$35

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Sanofi-Aventis U.S.Tzield$3,175
4 payments
  • Meals · 2025-10-14 · $144
  • Consulting · 2025-10-14 · $2,712
  • Meals for Tzield · 2025-07-13 · $170
  • Paid to speak or teach · 2025-06-21 · $150
GenzymeTzield$3,043
3 payments
  • Meals for Tzield · 2025-05-01 · $198
  • Consulting for Tzield · 2025-05-01 · $2,825
  • Travel for Tzield · 2025-05-01 · $20
See all 7 published payments
Every published payment
Sanofi-Aventis U.S.Meals · 2025-10-14None$144
Sanofi-Aventis U.S.Consulting · 2025-10-14None$2,712
Sanofi-Aventis U.S.Meals · 2025-07-13Tzield$170
Sanofi-Aventis U.S.Paid to speak or teach · 2025-06-21None$150
GenzymeMeals · 2025-05-01Tzield$198
GenzymeConsulting · 2025-05-01Tzield$2,825
GenzymeTravel · 2025-05-01Tzield$20
See earlier years (2024, 2023, 2022, 2019)

2024: $958

Payments by company in 2024
Sanofi-Aventis U.S.Tzield$958
5 payments
  • Meals for Tzield · 2024-01-19 · $43
  • Travel for Tzield · 2024-01-19 · $70
  • Travel for Tzield · 2024-01-18 · $474
  • Travel for Tzield · 2024-01-18 · $177
  • Meals for Tzield · 2024-01-18 · $194

2023: $6,319

Payments by company in 2023
Sanofi-Aventis U.S.Tzield$6,319
4 payments
  • Consulting for Tzield · 2023-11-10 · $6,088
  • Meals for Tzield · 2023-09-06 · $4
  • Meals for Tzield · 2023-06-23 · $113
  • Meals for Tzield · 2023-06-23 · $113

2022: $8,289

Payments by company in 2022
Novartis PharmaceuticalsPiqray$8,289
6 payments
  • Consulting for Piqray · 2022-11-21 · $400
  • Consulting for Piqray · 2022-08-08 · $686
  • Consulting for Piqray · 2022-06-10 · $1,544
  • Consulting for Piqray · 2022-03-30 · $3,344
  • Consulting · 2022-03-30 · $1,544
  • Consulting for Piqray · 2022-01-20 · $772

2019: $35

Payments by company in 2019
Medtronic MiniMedMinimed 670g System$35
1 payment
  • Meals for Minimed 670g System · 2019-03-01 · $35

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated With Alpelisib-Breast Cancer Res Treat · 2023This clinician$6,154
NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022This clinician$619
Novartis Pharmaceuticals Corporation · Byl-Ab -117225-Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With Pik3ca-Mutated, Hormone Receptor-Positive (Hr+), Human Epidermal Growth Factor Receptor 2-Negative (Her2?) Advanced Breast Cancer (Abc) Treated With Alp · 2023This clinician$396
F. Hoffmann-La Roche AG · Polygenic Risk Score Associations With Immune Checkpoint Inhibitors Related Endocrine Toxicity · 2024This clinician$176

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1861735714
Licence
CA A131799California A131799: Current · expires 2028-01-31
Group
UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Internal medicine (207R00000X); Student in a training program (390200000X)
Mailing address
400 Parnassus Ave. Ste 550, San Francisco, CA, 94143
NPI first listed
2013-03-28
NPI last updated
2019-07-09

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305